Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjd.16322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications.
iScience
September 2024
Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy with a high recurrence rate, significantly impacting prognosis and survival. This study aims to identify prognostic molecular markers using single-cell sequencing of tumors and adjacent tissues in primary and recurrent HCC patients. We analyzed single-cell sequencing data from tumor and adjacent normal tissues of primary and recurrent HCC cases to compare immune cell quantity and gene expression profiles.
View Article and Find Full Text PDFIGSF8 is an innate immune checkpoint and cancer immunotherapy target.
Cell
May 2024
Shanghai Xunbaihui Biotechnology Co., Ltd., 3rd floor of Building 4, No. 3728, Jinke Road, Pudong New Area, Shanghai, 201203, China. Electronic address:
Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune evasion and resistance to cancer immunotherapy, whereas how tumors evade innate immunity is less clear. Using CRISPR screens, we discovered that IGSF8 expressed on tumors suppresses NK cell function by interacting with human KIR3DL2 and mouse Klra9 receptors on NK cells. IGSF8 is normally expressed in neuronal tissues and is not required for cell survival in vitro or in vivo.
View Article and Find Full Text PDFHistopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
Cells
November 2023
Dermatology Unit & Scientific Directorate, Galliera Hospital, 16128 Genoa, Italy.
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients.
View Article and Find Full Text PDFDurable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Mol Cancer
July 2023
Molecular Biology Unit, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center - UNICANCER, Dijon, France.
Background: Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival on EGFR TKI treatment is between 12 and 14 months.
View Article and Find Full Text PDFMHC Class I Ligands of Rhesus Macaque Killer Cell Ig-like Receptors.
J Immunol
June 2023
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.
Article Synopsis
- - The study focuses on identifying the interactions between rhesus macaque killer cell Ig-like receptors (KIRs) and MHC class I molecules, which is crucial for understanding natural killer (NK) cell biology in these primates as they serve as important animal models for various fields.
- - Researchers tested rhesus macaque KIRs against different MHC class I alleles and discovered 12 KIRs with previously unknown specificities, categorizing their interactions primarily into three groups: those that bind to Mamu-Bw4, Mamu-A-related molecules, and Mamu-A1*012:01.
- - Most KIRs interacting with Mamu-Bw4 were inhibitory, while those binding to Mamu
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!